Ipilimumab N01
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer (NCT07506109) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-01 |
Track Ipilimumab N01 automatically
Every clearance here is in the API, with alerts when new ones post.